Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

1.840 +0.040 (+2.22%)
Streaming Delayed Price Updated: 9:30 AM EDT, Aug 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
20 21 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are rising and falling on Thursday as we check out all of the latest news worth knowing about this morning! 
Via InvestorPlace
Jaguar Health to Present October 3 at LD Micro's Main Event Investor Conference, and on October 5 at the Global Capital Network Investor Conference
Via ACCESSWIRE
Jaguar Health Launches TikTok and Instagram Contest to Raise Awareness About Common Yet Barely Addressed Health Condition: Surprise Diarrhea
Via ACCESSWIRE
Psyched: Steve Cohen Goes Big On Cybin, Fed Intervention On Psilocybin, Ketamine Insurance And More
Billionaire Steve Cohen Buys 19M Shares Of Cybin Stock For Psychedelics R&D, Blake Mycoskie $100M Pledge 
Via Benzinga
Topics Economy
Jaguar Health Shares Presentation Replay Link from September 11-13, 2023 H.C. Wainwright Annual Global Investment Conference
Via ACCESSWIRE
Patent Issued in Japan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)
Via ACCESSWIRE
Jaguar Health Shares Replay Link for September 7, 2023 Presentation at Emerging Growth Conference
Via ACCESSWIRE
Napo Pharmaceuticals Supports Groundbreaking Study on Quality of Life for Cancer Patients and Survivors
Via ACCESSWIRE
Peru's Coca Leaf Will Be Used For Research Toward Treating ADHD, Learn The Details
Magdalena Biosciences, Jaguar Health (NASDAQ: JAGX) and Filament Health (OTCQB: FLHLF) 
Via Benzinga
Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating ADHD
Via ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to National Institute of Allergy and Infectious Diseases for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Via ACCESSWIRE
Jaguar Health's Executive VP Dr. Karen Brunke Joins BIO's Rare Disease and Orphan Drugs Committee
Via ACCESSWIRE
Jaguar Health Engages B2i Digital to Deploy Cutting-Edge Investor Engagement Campaign
Via ACCESSWIRE
Jaguar Health Reports Second Quarter 2023 Financial Results
Via ACCESSWIRE
Jaguar Health to Hold Investor Webcast Monday, August 14th at 8:30 AM EDT Regarding Q2 2023 Financials & Corporate Updates
Via ACCESSWIRE
BioMedNewsBreaks – Jaguar Health Inc. (NASDAQ: JAGX) Announces Investor Engagement Campaign with B2i Digital
Via Investor Brand Network
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 59 companies achieved new lows for the year. 
Via Benzinga
The Science Times Publishes Article About Jaguar Health's Focus on Developing Crofelemer for Two Rare Disease Indications
Via ACCESSWIRE
Jaguar Health to Present September 7 at Emerging Growth Conference and at the September 11-13 H.C. Wainwright Annual Global Investment Conference
Via ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, Reports Completion of Last Patient Last Visit for its Pivotal Phase 3 OnTarget Trial of Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea
Via ACCESSWIRE
Napo Pharmaceuticals Surveys of Neurologists, Patients, and Caregivers Regarding Amyotrophic Lateral Sclerosis (ALS) Treatment Indicate Real World Burden of Diarrhea and Potential Treatment Interruption
Via ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
Via ACCESSWIRE
Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
Via ACCESSWIRE
Earnings Scheduled For August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million. 
Via Benzinga
Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea
Via ACCESSWIRE
Jaguar Health to Present Aug 4th at Wall Street Wonders Investment Group Luncheon in NYC
Via ACCESSWIRE
REMINDER: Napo Pharmaceuticals, a Jaguar Health Company, Supports Gay Men's Health with Participation in Pineapple Healthcare's "Butt Stuff Brunch with Dr. Carlton" August 5th
Via ACCESSWIRE
Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome (SBS)
Via ACCESSWIRE
In Honor of World Nature Conservation Day, Jaguar Health Announces Planting of More Than 1.1 Million Trees in Peruvian Amazon
Via ACCESSWIRE
Jaguar Health Names Principal Investigators for Clinical Trial to Support Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Via ACCESSWIRE
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.